Glimeto-MV2 Tablets

Composition

• Glimepiride – 2 mg
• Voglibose – 0.2 mg
• Metformin Hydrochloride (Sustained Release) – 500 mg

---

Mechanism of Action

Metformin Hydrochloride (SR) decreases hepatic glucose production, improves insulin sensitivity, and enhances peripheral glucose uptake. Its sustained-release formulation ensures gradual drug release for prolonged glycemic control with improved gastrointestinal tolerability.

Glimepiride stimulates insulin secretion from pancreatic beta cells, helping lower blood glucose levels effectively.

Voglibose inhibits intestinal alpha-glucosidase enzymes, delaying carbohydrate digestion and absorption, thereby reducing postprandial glucose spikes.

---

Key Benefits

• Triple-action approach for enhanced glycemic control
• Effective reduction of postprandial glucose spikes
• Improves insulin secretion and sensitivity
• Supports reduction in HbA1c levels
• Sustained-release formulation for prolonged effect
• Suitable for patients requiring intensified combination therapy

---

Indications

• Type 2 Diabetes Mellitus
• Patients inadequately controlled on dual therapy
• Advanced combination therapy for improved glycemic management

---

Dosage & Administration

• To be taken as directed by the physician
• Usually taken with meals
• Tablets should be swallowed whole and not crushed or chewed

---

Precautions

• Increased risk of hypoglycemia due to sulfonylurea component
• Gastrointestinal side effects may occur
• Use cautiously in renal or hepatic impairment
• Regular monitoring of blood glucose is recommended
• Avoid excessive alcohol intake

---

Contraindications

• Type 1 Diabetes Mellitus
• Diabetic ketoacidosis
• Severe renal or hepatic impairment
• Known hypersensitivity to any component

---

Storage

• Store in a cool and dry place below 25°C
• Protect from light and moisture
• Keep out of reach of children

---

Packaging

• 10 x 15 Tablets